Make your money go further for just 25p per day

Important Contract and £10m placing for Angle (AIM:AGL)

25/05/2016 · Angle Plc (AGL) 

There were two important announcements from Angle today (25 May). Firstly there was news that the Company has signed a contract with the University of Manchester, acting through the Cancer Research UK Manchester Institute, which will allow the incorporation of Angle’s Parsortix system for routine use in clinical trials and for research purposes. In a separate announcement, Angle reported that it had completed a placing with institutional investors to raise £10.2 million.

Angle (AIM: AGL)
http://www.angleplc.com/

Introduction
Angle is a specialist Medtech Company focused on commercialising its patented Parsortix liquid biopsy system. The Company believes that Parsortix has the potential to transform the diagnosis and treatment of cancer by making it possible to harvest intact cancer cells from a patient’s blood for analysis.

Investor’s Champion has reported on progress with Angle on a number of previous occasions - previous articles can be…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Angle Plc

Important Contract and £10m placing for Angle (AIM:AGL)

25/05/2016 · Company Insights
There were two important announcements from Angle today (25 May). Firstly there was news that the…

The Ten Bagger Quest - another string to Angle’s bow

21/03/2016 · Aimzine

​Significant progress with prostate cancer
By Michael Crockett

There was exciting news from Angle today. Bart’s Cancer…


More Company Insights

Elderly challenges | Demotion | Australian boost

21/11/2024 · Churchill China · CVS Group · Renold · Tracsis

Bonkers Bargains: poised to recover with a new CEO

20/11/2024 · James Cropper

Improving returns | Questionable business models

Sign-up to our free email updates

SIGN UP